Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Recruiting
N/A
Interventional Study
Venous Thromboembolic Disease
Pulmonary Embolism and Thrombosis
Deep Vein Thrombosis
Hospitalism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 110
- Sex
- Any
- Study type
- Interventional
- Purpose
- Health Services Research
- Participants needed
- 152,000 (estimated)
- Sponsor
- Scott C. Woller, MD · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal.
The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions:
* Physician, nurse practitioner, or physician assistant hospitalist
* Physician internal medicine
* Physician family medicine
* Patient age ≥ 18 y…
Contacts